<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02779166</url>
  </required_header>
  <id_info>
    <org_study_id>STU00067550</org_study_id>
    <nct_id>NCT02779166</nct_id>
  </id_info>
  <brief_title>Evaluation of Perioperative Celecoxib for Hip Arthroscopy</brief_title>
  <acronym>Celecoxib</acronym>
  <official_title>Evaluation of Perioperative Celecoxib for Hip Arthroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Celecoxib is commonly used for perioperative pain control for certain orthopaedic procedures.
      It has been shown to be successful in assisting in pain control for knee arthroscopy. It has
      not previously been studied in hip arthroscopy. This is a double blinded randomized
      controlled trial to determine the efficacy of celecoxib in perioperative pain control for hip
      arthroscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study examines the efficacy of perioperative dose of celecoxib in pain management after
      hip arthroscopy. Perioperative administration of celecoxib has been shown to improve pain
      control after knee arthroscopy, but this has not yet been studied in the hip. In this study,
      patients are randomized to receive either 400mg celecoxib or placebo 1 hour prior to
      undergoing hip arthroscopy surgery. Postoperatively, patients are monitored for pain on the
      VAS scale, narcotic use, and meeting discharge criteria. The study will enroll 100 patients.
      Patients are approached for informed consent on the day of surgery. Pain scores, narcotic
      use, and time to discharge in the celecoxib group are compared to the placebo group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Score for Pain (VAS) in the Immediate Post Operative Period</measure>
    <time_frame>Pre operative on day of surgery, immediately following OR close, 1 hr post operatively, 2 hrs post operatively</time_frame>
    <description>The pain VAS is a uni dimensional measure of pain intensity. It is a continuous scale comprised of a 0-10 pain rating. A score of 0 indicates no pain while a score of 10 would indicate extreme pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Narcotic Consumption in the Post Anesthesia Care Unit (PACU)</measure>
    <time_frame>duration of PACU stay,immediate post op period up to a maximum of 4 hours postoperatively</time_frame>
    <description>Monitored consumption of narcotic medications following surgery, measured in morphine equivalents</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Discharge Following Surgery</measure>
    <time_frame>time from OR to discharge, up to a maximum of 6 hours postoperatively</time_frame>
    <description>Total time to discharge from OR close following surgery, measured in minutes</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Hip Labral Tears</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received 400mg celecoxib prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Received placebo pill prior to surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Received 400mg celecoxib prior to surgery</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients who are undergoing a hip arthroscopy procedure at Northwestern Memorial
             Hospital with Dr. Michael Terry.

        Exclusion Criteria:

          -  Pregnant women and any patient under the age of 18 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Terry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 13, 2016</study_first_submitted>
  <study_first_submitted_qc>May 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2016</study_first_posted>
  <results_first_submitted>February 13, 2017</results_first_submitted>
  <results_first_submitted_qc>April 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 14, 2019</results_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Michael Terry</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>hip arthroscopy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>50 patients received 400mg celecoxib prior to surgery
Celecoxib: Received 400mg celecoxib prior to surgery</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>48 received placebo pill prior to surgery
placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>Received 400mg celecoxib prior to surgery
Celecoxib: Received 400mg celecoxib prior to surgery</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Received placebo pill prior to surgery
placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.2" spread="11.9"/>
                    <measurement group_id="B2" value="35.8" spread="11.6"/>
                    <measurement group_id="B3" value="35.0" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Analog Score for Pain (VAS) in the Immediate Post Operative Period</title>
        <description>The pain VAS is a uni dimensional measure of pain intensity. It is a continuous scale comprised of a 0-10 pain rating. A score of 0 indicates no pain while a score of 10 would indicate extreme pain.</description>
        <time_frame>Pre operative on day of surgery, immediately following OR close, 1 hr post operatively, 2 hrs post operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>50 patients received 400mg celecoxib prior to surgery
Celecoxib: Received 400mg celecoxib prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>48 received placebo pill prior to surgery
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Score for Pain (VAS) in the Immediate Post Operative Period</title>
          <description>The pain VAS is a uni dimensional measure of pain intensity. It is a continuous scale comprised of a 0-10 pain rating. A score of 0 indicates no pain while a score of 10 would indicate extreme pain.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Operative VAS Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="2.06"/>
                    <measurement group_id="O2" value="2.33" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immediate Post Op VAS Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.41" spread="3.00"/>
                    <measurement group_id="O2" value="5.02" spread="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr Post Op VAS Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" spread="1.91"/>
                    <measurement group_id="O2" value="5.36" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr Post Op VAS Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.11" spread="1.75"/>
                    <measurement group_id="O2" value="4.92" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Narcotic Consumption in the Post Anesthesia Care Unit (PACU)</title>
        <description>Monitored consumption of narcotic medications following surgery, measured in morphine equivalents</description>
        <time_frame>duration of PACU stay,immediate post op period up to a maximum of 4 hours postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>50 patients received 400mg celecoxib prior to surgery
Celecoxib: Received 400mg celecoxib prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>48 received placebo pill prior to surgery
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Narcotic Consumption in the Post Anesthesia Care Unit (PACU)</title>
          <description>Monitored consumption of narcotic medications following surgery, measured in morphine equivalents</description>
          <units>morphine milligram equivalents</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.326" spread="11.0"/>
                    <measurement group_id="O2" value="15.419" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Discharge Following Surgery</title>
        <description>Total time to discharge from OR close following surgery, measured in minutes</description>
        <time_frame>time from OR to discharge, up to a maximum of 6 hours postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>50 patients received 400mg celecoxib prior to surgery
Celecoxib: Received 400mg celecoxib prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>48 received placebo pill prior to surgery
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discharge Following Surgery</title>
          <description>Total time to discharge from OR close following surgery, measured in minutes</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.9" spread="55.2"/>
                    <measurement group_id="O2" value="172.9" spread="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>50 patients received 400mg celecoxib prior to surgery
Celecoxib: Received 400mg celecoxib prior to surgery</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>48 received placebo pill prior to surgery
placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael Terry</name_or_title>
      <organization>Northwestern Univeristy Department of Orthopaedic Surgery</organization>
      <phone>312-926-4444</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

